US Stock Movement: Alpha Tek Holdings plummets on October 30 — Q3 misses on both fronts, guidance lowered, biologics weakness

Alphatec Holdings October 30 Sharp Drop Analysis

Keywords: Q3 miss, guidance downgrade, weak biologics

1. After the market closed on October 29, 2026, Alphatec announced its third quarter results: revenue was $221.2 million, below market expectations of $224.3 million; adjusted earnings per share were $0.09, below estimates of $0.11.

2. On October 29, 2026, the company lowered its 2026 fiscal year revenue guidance from $882 million to $862 million, and mentioned a decline in biologics attachment rates, softer thoracolumbar procedure volumes, and a sterile implant packaging defect causing about $3 million in international supply chain impact.

3. On October 30, 2026, BMO Capital downgraded its rating from Outperform to Market Perform, and reduced the target price from $12 to $8; Needham maintained a Buy rating but lowered the target price from $14 to $12.

(Disclaimer: This content is compiled by AI technology from public information for reference only and does not constitute investment advice.)